BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » stem cell research

Does Your Stem Cell Market Intelligence Utilize Futuristic Techniques?

December 4, 2017 By Cade Hildreth (CEO) Leave a Comment

DOES YOUR STEM CELL MARKET INTELLIGENCE PROVIDER USE FUTURISTIC TECHNIQUES?

2017 has never seen more opportunity for analysis of data, as the total global amount of data is now estimated to be 1.2 zettabytes.

Therefore, techniques for managing analysis of data must dynamically evolve.

While you may not understand the precise meaning of research terms such as meta-analysis, algorithmic analysis, or predictive trend analysis, it is important to ask yourself, are you embracing new and evolving methods for sourcing market data?

Futuristic (Definition): “Having or involving very modern technology or design”

Whether you are conducting your own market research or outsourcing it to a third-party, you should get clear answers to the following: [Read more…]

Filed Under: Stem Cells Tagged With: futuristic, market research, market research provider, market trends, stem cell, stem cell research

Breaking Stem Cell News, Featuring Cynata, ORIG3N, Cellular Dynamics, Commence Bio, and More

July 8, 2016 By Cade Hildreth (CEO) Leave a Comment

You need stem cell news. We have breaking stories. - Depositphotos_7553939_m-2015-1.jpg

This week stem cell industry participants announced major collaborations, patent awards, research advances, and more. Check out our stem cell industry coverage below and let me know what you think. Enjoy!

Interview with Paul Wotton, Current Board Member of Cynata Therapeutics and Previous President/CEO of Ocata Therapeutics

This is an exclusive interview with Dr. Paul Wotton, who joined Cynata Therapeutics (ASX: CYP) Board of Directors in June of 2016. Cynata is an Australian company that is developing a therapeutic stem cell platform technology originating from the University of Wisconsin-Madison that utilizes iPSCs are starting material for generating nearly unlimited quantities of MSCs. Dr. Wotton was previously President and CEO of Ocata Therapeutics, joining the company in July 2014 and managing it through an all-cash take-over by Atellas Pharma valued at $379 million.

ORIG3N and Kangstem Biotech Partner to Investigate Induced Neural Stem Cells for Disease Modeling

Boston biotech company ORIG3N has announced a collaboration with South Korea’s Kangstem Biotech in a joint effort to gain insight into the effectiveness of induced neural stem cells (iNSC) in disease modeling. As a pioneer of regenerative medicine, ORIG3N is leading the way towards the future of medicine by crowdsourcing blood samples to create the world’s largest and most diverse biorepository of stem cells. As part of this collaboration, Kangstem Biotech will be providing iNSC’s to ORIG3N for research.

CDI and National Eye Institute to Collaborate on iPSC-Derived Cell Therapies for Retinal Degenerative Disease

Cellular Dynamics International (CDI), a FUJIFILM company, announced that it has entered into a Cooperative Research and Development Agreement with the National Eye Institute, a division of the NIH, to conduct research to advance a cell transplantation therapy for the treatment of retinal degenerative disease using retinal pigment epithelium derived from induced pluripotent stem cells (iPSC-RPE). The collaboration includes the joint development of an optimized biocompatible biodegradable scaffold that is likely to be a critical component for a potential future therapy.

Commence Bio Receives 1st Patent for MSC1, An Innovative Cancer Immunotherapy Platform

Commence Bio announced that the company has received its first patent for MSC1.
Commence Bio is a pre-clinical stage biotechnology company that is based on the concept that cancer and other inflammatory conditions can be addressed by “rebooting patients’ immune systems” with a new class of medicinal stem cells, MSC1 and MSC2. The company is now developing a therapeutic pipeline, as well as offering research products that include MSC1 and MSC2 cells and media.

Do You Know the Top “Quality Guarantees” Among U.S. Cord Blood Banks?

A characteristic that can distinguish one cord blood bank from another is the amount of its quality guarantee. Currently, the top cord blood banks in the U.S offer quality guarantee packages that range from $25,000 – $90,000, with Americord topping that list at $90,000. Interestingly, Americord raised its guarantee from $80,000 to $90,000 in mid-2014 to further separate itself from the competition and increase its trustworthiness in the eyes of its clients. The primary reason for a cord blood bank to offer a quality guarantee is to reassure prospects that banking their children’s cord blood is a protected investment.

Mesenchymal Stem Cells – Advances & Applications [Global Strategic Report; 250 Pages]

As of July 2016, our highest-demand market report is “Mesenchymal Stem Cells – Advances & Applications.” You should view it because: 1) MSCs are one of the fastest growing areas of stem cell research, 2) MSCs are now more frequently cited than any other stem cell type within the scientific literature, and 3) Google Trend data shows MSC searches to be approximately twice as common as the next most common adult stem cell type. The market for MSCs is growing. Are you informed about market opportunities and ready to act on them now?

About BioInformant

BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.

Filed Under: Stem Cells Tagged With: stem cell research, stem cell technology, stem cells

Mesenchymal Stem Cell Industry News Round Up | October 2015

October 14, 2015 By Cade Hildreth (CEO) Leave a Comment

MESENCHYMAL STEM CELL INDUSTRY NEWS ROUND UP | OCTOBER 2015

The mesenchymal stem cell (MSC) industry is well-known for its shifting dynamics, including new alliances, new research advances and innovations. Every month there are major new events that affect market participants.

Therefore, we are excited to share with you the following summary of major mesenchymal stem cell (MSC) industry events for  October 2015.

[Read more…]

Filed Under: MSCs Tagged With: current events, industry news, market research, mesenchymal stem cells, MSC, news round up, stem cell research

Dental Pulp Stem Cell News Round-Up | 3rd Quarter 2015

July 8, 2015 By Cade Hildreth (CEO) Leave a Comment

DENTAL PULP STEM CELLS NEWS ROUND-UP | 2ND QUARTER 2015

The dental pulp stem cell industry is a rapidly evolving industry. Every month there are major events occurring in the sector that shift industry dynamics. Often, these events are announcements of technical or scientific advancements.  Sometimes they are announcements of major industry alliances. Occasionally, they are announcements of a new industry competitor, a major milestone, or a significant funding award.

For those of us interested in the dental pulp stem cell industry, tracking these shifting industry dynamics is of paramount importance.  For this reason, this post covers the most significant neural stem cell industry news events as of July 2015.

[Read more…]

Filed Under: Stem Cells Tagged With: dental pulp stem cell, dental pulp stem cell transplants, industry news, market research, stem cell research, Tooth Bank

“Blockbuster” Year for Induced Pluripotent Stem Cells Provides Expanding Opportunities, with Japan at the Forefront of Global Innovation

June 26, 2015 By Cade Hildreth (CEO) Leave a Comment

"Blockbuster" Year for Induced Pluripotent Stem Cells Provides Expanding Opportunities, with Japan at the Forefront of Global Innovation

To create profitable products and services, stem cell industry executives need to stay informed about rapidly-evolving industry trends. For this reason, this post explores important trends, events, and metrics of importance within the induced pluripotent stem cell (iPSC) industry. It also considers geographical dominance within the industry.
[Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: induced pluripotent stem cells, industry trends, iPS cells, iPSC clinical applications, iPSC development, iPSC industry, iPSCs, Japan, stem cell research, United States

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.